MedTrace Logo

A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty

NCT00411515 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2006-12-15

No results posted yet for this study

Summary

The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty.

The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.

Conditions

  • Corneal Transplantation

Interventions

DRUG

Mycophenolate Mofetil 2x 1g

Sponsors & Collaborators

Principal Investigators

  • Thomas Reinhard, Prof. MD · University Eye Hospital, Freiburg

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00411515 on ClinicalTrials.gov